The 30 references in paper M. Ketteler, K. Martin J., M. Volf , M. Amdahl, M. Cozzolino , D. Goldsmith , A. Sharma , S. Marks, S. Khan, М. Кеттелер, К. Мартин Дж., М. Вольф, М. Амдаль, М. Коццолино, Д. Голдсмит, А. Шарма, С. Маркс, С. Хан (2012) “ПАРИКАЛЬЦИТОЛ В СРАВНЕНИИ С ЦИНАКАЛЬЦЕТОМ В СОЧЕТАНИИ С НИЗКИМИ ДОЗАМИ ВИТАМИНА D В ЛЕЧЕНИИ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА У ПАЦИЕНТОВ НА ГЕМОДИАЛИЗЕ: РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ IMPACT SHPT // PARICALCITOL COMPARED TO CINACALCET WITH LOW-DOSE VITAMIN D THERAPY FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HAEMODIALYSIS: RESULTS OF THE IMPACT SHPT RESEARCH” / spz:neicon:nefr:y:2012:i:4:p:28-38

1
Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-F264
(check this in PDF content)
2
Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007; 13: 397-411
(check this in PDF content)
3
Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885
(check this in PDF content)
4
Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
(check this in PDF content)
5
Naves-Diaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947
(check this in PDF content)
6
Floege J, Kim J, Ireland E et al. ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
(check this in PDF content)
7
Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73: 1296-1302
(check this in PDF content)
8
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38. Erratum in: Kidney Int 2009; 75: 1237
(check this in PDF content)
9
Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013
(check this in PDF content)
10
Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1529-1539
(check this in PDF content)
11
Kalantar-Zadeh K, Miller JE, Kovesdy CP et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients. J Bone Miner Res 2010; 25: 2724-2734. Erratum in: J Bone Miner Res 2011; 26: 439
(check this in PDF content)
12
Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodi-alysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
(check this in PDF content)
13
Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355-1363
(check this in PDF content)
14
Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
(check this in PDF content)
15
Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078
(check this in PDF content)
16
Tentori F, Hunt WC, Stidley CA et al. Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865
(check this in PDF content)
17
Sensipar® (Cinacalcet) Tablets [Prescribing Information]. Thousand Oaks, CA: Amgen Inc., 2010. http://pi.amgen.com/ united_states/sensipar/ sensipar_pi_hcp_english.pdf (7 July 2010, date last accessed)
(check this in PDF content)
18
Lund RJ, Andress DL, Amdahl M et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31: 165-170
(check this in PDF content)
19
Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
(check this in PDF content)
20
Ross EA, Tian J, Abboud H et al. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106
(check this in PDF content)
21
Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776
(check this in PDF content)
22
Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl JMed 2004; 350: 1516-1525
(check this in PDF content)
23
Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment sig-nificantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78: 578-589
(check this in PDF content)
24
Block GA, Zeig S, Sugihara J et al. Combined therapy with cinacalcet and low doses ofvitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23: 2311-2318
(check this in PDF content)
25
Fishbane S, Shapiro WB, Corry DB et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718-1725
(check this in PDF content)
26
Ketteler M, Martin KJ, Cozzolino M et al. Paricalcitol- versus cinacalcet-centered therapy for secondary hyperparathyroidism in patients receiving hemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrol Dial Transplant 2012; doi:10.1093/ndt/gfr531
(check this in PDF content)
27
Jacome-Galarza CE, Lee SK, Lorenzo JA et al. Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic pro-genitors in the bone marrow. J Bone Miner Res 2011; 26: 1207-1216
(check this in PDF content)
28
Kalantar-Zadeh K, Shah A, Duong U et al. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010; 117: S10-S21
(check this in PDF content)
29
Fahrleitner-Pammer A, Herberth J, Browning SR et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008;23: 1850-1858
(check this in PDF content)
30
Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011 Поступила в редакцию 25.04.2012 г. Принята в печать 11.10.2012 г.
(check this in PDF content)